Showing results (221-230 of 279) with videos related to
Sort By:
Pageof 28
Medrxiv : the Preprint Server for Health Sciences|February 6, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancerMatthew D Galsky, Sudeh Izadmehr, Menggang Yu, et al.European Urology|January 12, 2020
Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized StudyDaniel W Lin, Mei-Chiung Shih, William Aronson, et al.Journal of the National Cancer Institute|December 6, 2017
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate CancerAlexander W Wyatt, Matti Annala, Rahul Aggarwal, et al.Science (New York, N.Y.)|April 11, 2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancerChris Tran, Samedy Ouk, Nicola J Clegg, et al.Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupHoward I Scher, Susan Halabi, Ian Tannock, et al.Molecular Cancer Research : MCR|March 29, 2019
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass HeterogeneityRahul R Aggarwal, David A Quigley, Jiaoti Huang, et al.Clinical Genitourinary Cancer|June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate CancerTerence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.Pageof 28